Jefferies Financial Group Inc. Acquires Shares of 642,123 Pfizer Inc. $PFE

Jefferies Financial Group Inc. acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 642,123 shares of the biopharmaceutical company’s stock, valued at approximately $15,462,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new position in Pfizer in the 2nd quarter valued at about $56,549,000. MASTERINVEST Kapitalanlage GmbH bought a new stake in Pfizer during the 2nd quarter worth approximately $1,371,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of Pfizer in the second quarter worth approximately $90,000. Blue Edge Capital LLC purchased a new stake in shares of Pfizer in the second quarter worth approximately $208,000. Finally, Strive Financial Group LLC lifted its holdings in shares of Pfizer by 29.9% in the second quarter. Strive Financial Group LLC now owns 9,474 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 2,181 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Pfizer Stock Performance

PFE stock opened at $28.00 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market cap of $159.62 billion, a PE ratio of 36.85 and a beta of 0.34. The business has a 50 day moving average of $25.49 and a 200-day moving average of $26.29. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $0.78 earnings per share. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is presently 226.32%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and decreased their price target for the stock from $32.00 to $28.00 in a report on Monday, July 6th. Weiss Ratings cut Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. Guggenheim cut their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, August 7th. JPMorgan Chase & Co. reduced their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Finally, Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.